Industry News CG Oncology BioSpace

CG Oncology's Bladder Cancer Virus Cuts Recurrence Risk by Two-Thirds in Phase 3

  • Topline PIVOT-006 data: the oncolytic immunotherapy cretostimogene cut recurrence risk by 68% versus surveillance in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer.
  • The randomized study enrolled 367 patients; the company reports no grade 3 or higher treatment-related adverse events.
  • A second BLA is planned for Q2 2027; full data go to the Society of Urologic Oncology meeting on December 2.
Points Based on public reports

This moves cretostimogene from the BCG-unresponsive niche into a far larger adjuvant population with no approved option, which is what the stock is really pricing. The caveats: the control arm is surveillance, not an active drug, and median follow-up is only 17 months, so durability is open. Compare it against intravesical rivals once full data show how many patients needed repeat dosing.